Exam OG0-093 All QuestionsBrowse all questions from this exam
Question 312

Scenario -

Please read this scenario prior to answering the Question

You have been appointed as a consultant to the Chief Enterprise Architect of a multinational corporation. The corporation has over 100,000 employees and is organized into 10 divisions with operation in over 60 countries and products sold in over 125 countries. It has major research sites at 8 locations worldwide.

The operations of the corporation are subject to legal and regulatory requirements for each country where they operate. The production of its products has governmental controls that are strictly enforced and compliance is critical. Recently a competitor was heavily fined for violating the regulations in a country where it was conducting a trial for a new product.

The Enterprise Architecture group within the company has been engaged in an architecture development system that will allow researchers at its product development laboratories worldwide to share information about their clinical trials. This system will also connect with external partners.

The Enterprise Architecture group is a mature organization. They use the TOGAF ADM with extensions required to support the manufacturing practices and laboratory practices of their target markets. Due to the highly sensitive nature of the information that is managed, special care was taken to ensure that each architecture domain included an examination of the security, regulatory and privacy issues that are relevant.

The Executive Vice President for Clinical Research is the sponsor of the Enterprise Architecture activity. She has stated that the changes to the Enterprise

Architecture for the new system will need to be rolled out on a geographic basis that will minimize disruptions to ongoing clinical trials. The work will need to be done in stages and rolled out in geographical regions.

Refer to the Scenario -

You have been asked to recommend the approach to identify the work packages that will be included in the Transition Architecture (s)

Based on the TOGAF standard, which of the following is the best answer?

    Correct Answer: C

    The best approach to identify the work packages that will be included in the Transition Architecture involves documenting the factors impacting the implementation and Migration Plan. For each gap identified in the domain architecture gap analysis, a proposed solution must be identified and classified as new development, purchased solution, or based on an existing product. Similar solutions should be grouped together to form work packages, while dependencies between these work packages need to be identified factoring in the clinical trial schedules. Finally, the work packages should be regrouped into a set of Capability Increments scheduled into a series of Transition Architectures. This comprehensive approach ensures a well-structured roll-out plan that considers both clinical trial schedules and geographic implementation.

Discussion
noureldinOption: C

Ans C should better than A: A doesn't talk about transition architecture, and TOGAF recommends to "Using the Consolidated Gaps, Solutions, and Dependencies matrix together with the Implementation Factor Assessment and Deduction matrix, logically group the various activities into work packages

RVROption: C

Answer should be C or D, I am unsure why its not C as its a more complete process. The question is " recommend the approach to identify the work packages " and the answer is to use Consolidated Gaps, Solutions and Dependencies Matrix as its the right tool 'used as a planning tool when creating work packages' But C takes it one step forward and completes the process by "Document the progression of the enterprise architecture using a state evolution table" as well as it lists "rollout one region at a time" which is a requirement. I would go with C.

RVR

Sorry, got the alphabets wrong. Its between A and D and I was inclined towards D.

BanzaaaiOption: C

impacting the implementation and Migration Plan

nemOption: C

I would go with C as it is aligned to the steps of phase E. You need to do the Implementation Factor Assessment & Deduction Matrix first to be able to group the work packages into capability increments and finalize the transition architectures. Answers A and D simply ignore the key implementation factors in the scenario

sreejayanOption: D

I will go with D

RVROption: D

Why is it not D ?

hkwongOption: C

C. Considered the clinical trial schedules factor and transition Architecture.

IyoOption: A

The Answer is A. Read https://guides.visual-paradigm.com/togaf-adm-top-10-techniques-part-5-migration-planning-techniques/#:~:text=Overall%2C%20the%20Implementation%20Factor%20Assessment,any%20potential%20issues%20or%20constraints. This explains the difference and purpose of Consolidated Gaps, Solutions, and Dependencies Matrix vs Implementation Factor Assessment and Deduction Matrix.

Iyo

I think C is correct. Takes care of Transition Architecture, A doesn't.

youthanasiaOption: D

D is the best answer, it satisfies the work packages and the regional rollout that is requested